PMID- 36249112
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221019
IS  - 2251-6093 (Electronic)
IS  - 2251-6085 (Print)
IS  - 2251-6085 (Linking)
VI  - 51
IP  - 8
DP  - 2022 Aug
TI  - Local Estrogen Therapy for Pelvic Organ Prolapse in Postmenopausal Women: A 
      Systematic Review and Meta-Analysis.
PG  - 1728-1740
LID - 10.18502/ijph.v51i8.10255 [doi]
AB  - BACKGROUND: The prevalence of pelvic organ prolapse (POP) is expected to increase 
      in the next few decades, imposing a substantial medical burden. The effect of 
      local estrogen therapy (LET) on POP in postmenopausal women is still 
      controversial; therefore, we aimed to provide reliable evidence to address this 
      issue from the perspective of vaginal health and quality of life (QoL). METHODS: 
      We searched in the PubMed, the Web of Science, Embase and the Cochrane Library 
      databases for eligible RCTs from beginning to Apr 2021. The Preferred Reporting 
      Items for Systematic Reviews and Meta-Analyses guidelines were followed in our 
      study. RESULTS: Seven RCTs(n=570) were included. No significant improvement of 
      the epithelial thickness (SMD=1.38, 95%CI -0.54 to 3.31, P=0.16) or vaginal pH 
      (SMD=-0.98, 95%CI -2.65 to 0.69, P=0.25) after LET compared with the control. A 
      slight increase was observed in the VMI (MD=16.58, 95%CI 1.14 to 32.02, P=0.04). 
      Regarding QoL, no significant differences between the estrogen group and the 
      control group in PFIQ-7 (6m: MD=3.60, 95%CI -3.13 to 10.33, P=0.29; 12m: MD=3.53, 
      95%CI -3.35 to 10.41, P=0.31), PISQ-12(6m: MD=0.62, 95%CI -0.73 to 1.98, P=0.37; 
      12m: MD=0.36, 95%CI -1.06 to 1.77, P=0.62), or PGI-I (6m: RR=0.99, 95%CI 0.92 to 
      1.07, P=0.88; 12m: RR=1.01, 95%CI 0.95 to 1.07, P=0.72) score. Moreover, no more 
      specific adverse events (AEs) (RR=1.11, 95%CI 0.84 to 1.48, P=0.46) were observed 
      in the interventional group. CONCLUSION: Not find LET caused either a significant 
      improvement in vaginal health and QoL or more AEs.
CI  - Copyright (c) 2022 Yu et al. Published by Tehran University of Medical Sciences.
FAU - Yu, Xia
AU  - Yu X
AD  - Chengdu Women's and Children's Central Hospital, Sichuan Provincial People's 
      Hospital, School of Medicine, University of Electronic Science and Technology of 
      China, Chengdu, China.
FAU - He, Li
AU  - He L
AD  - Chengdu Women's and Children's Central Hospital, School of Medicine, University 
      of Electronic Science and Technology of China, Chengdu, China.
FAU - Wang, Yanjun
AU  - Wang Y
AD  - Chengdu Women's and Children's Central Hospital, School of Medicine, University 
      of Electronic Science and Technology of China, Chengdu, China.
FAU - Wang, Li
AU  - Wang L
AD  - Chengdu Women's and Children's Central Hospital, School of Medicine, University 
      of Electronic Science and Technology of China, Chengdu, China.
FAU - Yang, Zhenglin
AU  - Yang Z
AD  - Sichuan Provincial People's Hospital, University of Electronic Science and 
      Technology of China, Chengdu, China.
FAU - Lin, Yonghong
AU  - Lin Y
AD  - Chengdu Women's and Children's Central Hospital, School of Medicine, University 
      of Electronic Science and Technology of China, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Iran
TA  - Iran J Public Health
JT  - Iranian journal of public health
JID - 7505531
PMC - PMC9546820
OTO - NOTNLM
OT  - Estrogen
OT  - Pelvic organ prolapse
OT  - Postmenopausal women
OT  - Quality of life
OT  - Vaginal health
COIS- Conflict of interests The authors declare that there is no conflict of interest.
EDAT- 2022/10/18 06:00
MHDA- 2022/10/18 06:01
PMCR- 2022/08/01
CRDT- 2022/10/17 05:18
PHST- 2022/01/09 00:00 [received]
PHST- 2022/03/17 00:00 [accepted]
PHST- 2022/10/17 05:18 [entrez]
PHST- 2022/10/18 06:00 [pubmed]
PHST- 2022/10/18 06:01 [medline]
PHST- 2022/08/01 00:00 [pmc-release]
AID - IJPH-51-1728 [pii]
AID - 10.18502/ijph.v51i8.10255 [doi]
PST - ppublish
SO  - Iran J Public Health. 2022 Aug;51(8):1728-1740. doi: 10.18502/ijph.v51i8.10255.